Alzheimer’s disease is developing continuously in a stage of degeneration of brain cells gradually. It is the most common cause of dementia- a severe memory loss and impairment of thinking and behavior and disrupts social activity due to improper functional carry out tasks. Firstly, the disease may spread by forgetting the activities, tasks, and conversations. There is no cure of Alzheimer’s disease and alters the effect of prone disease in the brain. In advanced stages of the disease, complications from severe loss of brain function — such as dehydration, malnutrition or infection — result in death.
A new study had done by scientists revealed the potential way to reduce the risk of disease. The research showed that aggressive treatment of severe herpes infection with antiviral medication or treatment drastically lowers Alzheimer’s risk significantly by 10 times.
Manchester’s Professor Ruth Itzhaki and Edinburgh’s Professor Richard Lathe found the research and published in Neurotherapeutics in February 2018, also shows that herpes simplex virus type 1 (HSV1) leads to an increased risk of developing the disease. The other two kinds of research by different research groups in Taiwan provide the population evidence for a causal link between herpes virus infection and Alzheimer’s disease by professor Itzhaki.
Almost 30 million people worldwide suffer from it and the number gradually increases and no effective treatments are yet available for it. To combat the disease, the safe and easily available antiviral vaccination raises the future possibility of preventing the disease. After the vaccination during the infancy age, when they will grow up on their age are free from the infectious disease.
HSV1 infects most humans in youth or later and remains lifelong in the body in dormant form within the peripheral nervous system. Its main characteristic of causing visible damage in form of cold sores when the virus becomes activated from time to time.
The Taiwanese study identified 8,362 subjects aged 50 or more during the period January to December 2000 who were newly diagnosed with severe HSV infection.
The study group was compared to a control group of 25,086 people with no evidence of HSV infection.
The authors then monitored the development of dementia in these individuals over a follow-up period of 10 years between 2001 and 2010.
The risk of developing dementia in the HSV group was increased by a factor of 2.542. But, when the authors compared those among the HSV cohort who were treated with antiviral therapy versus those who did not receive it, there was a dramatic tenfold reduction in the later incidence of dementia over 10 years.